Dabrafenib in patients with BRAF -mutated non-small cell lung cancer

Lung cancer is the leading cause of cancer death worldwide and non-small cell lung cancer (NSCLC) accounts for more than 85% of all cases of lung cancer. Molecular targeted drugs, which specifically inhibit a particular molecular target, have been developed actively and have contributed to improved outcomes of advanced NSCLC patients. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (e.g., gefitinib, erlotinib, icotinib, afatinib, olmutinib and osimertinib) and anaplastic lymphoma kinase (ALK) TKIs (e.g., crizotinib, ceritinib and alectinib) have been reported to demonstrate dramatic efficacy in patients with EGFR mutation-positive and ALK-rearranged advanced NSCLC, respectively. However, other targeted treatment options for patients with advanced NSCLC have so far been limited